Investigational drug · Phase 2
JAB-2485
Also called: Aurora A inhibitor
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "JAB-2485"
First trial start
2022
Dec 20, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JAB-2485", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- ER+ Breast Cancer
- Triple Negative Breast Cancer, TNBC
- ARID1A Gene Mutation
- Small Cell Lung Cancer, SCLC
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JAB-2485" as an intervention, largest first.
Jacobio Pharmaceuticals Co., Ltd.Industry
NCT05490472 · 102 participants (planned) · Start Dec 20, 2022 · Primary completion Aug 2026
Drug: JAB-2485 (Aurora A inhibitor); JAB-2485 (Aurora A inhibitor) · For: Solid Tumors; ER+ Breast Cancer; Triple Negative Breast Cancer, TNBC and 2 more
Sites: Detroit, Michigan; St Louis, Missouri; Dallas, Texas · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- In silico identification and biological evaluation of newly synthetic hinokiflavone derivatives as multi-kinase inhibitors with preferential Aurora A activity for ovarian cancer therapy.
Wang K, Chen GY, Chu PY, et al. · Eur J Med Chem 2026
- Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells.
Yapindi L, Ghosh S, Shen L, et al. · Clin Cancer Res 2026
- Targeting Aurora A Kinase Enhance the CDK4/6 Inhibitor Sensitivity in HR+/HER2- Breast Cancer.
Wu J, Wang Y, Yan H, et al. · Oncol Res 2026
- Discovery of Potent and Selective Pyrrolo[2,3-d]Pyrimidine-Based Aurora A Inhibitors with Demonstrated Efficacy against Patient-Derived Gastric Cancer Organoids.
Zhang R, Yu T, Zhang M, et al. · J Med Chem 2025
- Aurora-A inhibits hepatocellular carcinoma cell ferroptosis to mediate immune escape by disrupting phosphatidylethanolamine biosynthesis.
Fan L, Liu Y, Cai Y, et al. · Am J Cancer Res 2025
- Boron Phenylalanine-Modified Polydopamine Nanoparticles for Targeted Delivery of Danusertib in Non-Small Cell Lung Cancer.
Xu Y, Chen X, Zhang L, et al. · Int J Nanomedicine 2025
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.